Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Short Interest Declined By 29.29%

May 3, 2018 - By Rebecca Betts

Big Money Sentiment decreased to 1.17 in Q4 2017. It has change of 0.26, from 2017Q3’s 1.43. The ratio worsened due to Vanda Pharmaceuticals Inc. positioning: 19 sold and 34 reduced. 16 funds acquired stakes and 46 increased stakes. Investors holded 38.89 million in 2017Q3 but now own 39.77 million shares or 2.28% more.
Panagora Asset invested in 268,534 shs. Susquehanna Group Inc Llp has 27,448 shs. Point72 Asia (Hong Kong) Limited has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Los Angeles Equity Rech invested in 37,597 shs or 0% of the stock. Financial Bank Of America De reported 0% stake. Piermont Mgmt Inc accumulated 14,750 shs or 0.07% of the stock. Ontario – Canada-based Manufacturers Life Insur The has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Credit Suisse Ag reported 0% of its capital in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Kistler stated it has 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Venbio Select Advisor Limited Liability Corporation accumulated 1.41M shs. Gemmer Asset Mngmt Limited Co reported 594 shs. Cadence Capital Management holds 0.11% or 109,074 shs. Northern Trust has 578,031 shs. 36,241 were reported by Parametric Portfolio Associate Limited Liability. Ameriprise has 87,646 shs for 0% of their capital.

Vanda Pharmaceuticals Inc. had 8 insider sales and 0 buys since January 2, 2018. This’s net activity of $4.89 million. Gulino Richard L. sold 10,367 shs worth $157,565. The insider Birznieks Gunther sold $130,777. 191,760 shs were sold by Polymeropoulos Mihael Hristos, worth $2.93M on Tuesday, January 2.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) had a decrease of its short interest by 29.29%. FINRA announced in May VNDA’s total 2.38M short interest. The down change of 29.29% from 3.37M shares was reported. Vanda Pharmaceuticals Inc (NASDAQ:VNDA) has 1.24M shares average volume. It’ll cost 2 days for VNDA to restore its former position. Vanda Pharmaceuticals Inc float short is 6.02%.

VNDA is hitting $15.25 during the last trading session, after increased 9.32%.Vanda Pharmaceuticals Inc. has 1.27 million shares volume, 75.42% up from normal. VNDA is uptrending and has moved 15.63% since May 3, 2017. VNDA outperformed the S&P 500 by 4.08%.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders.The firm is worth $794.69 million. The company??s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia.Last it reported negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

A total of 3 analysts rate Vanda (NASDAQ:VNDA) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:VNDA) has 6 ratings reports on May 3, 2018 according to StockzIntelligence. On Wednesday, February 28 the stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Seaport Global. On Sunday, November 12 the stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given by Oppenheimer. In Monday, January 8 report Oppenheimer maintained the stock with “Buy” rating. In Monday, March 5 report Oppenheimer maintained it with “Buy” rating and $27.0 target. On Tuesday, February 13 the stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.